Toolbox Cognitive Battery News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail
An experimental treatment produced improvements in cognitive function and language in patients with fragile X syndrome, according to study results published on April 29 in
Nature Medicine. Fragile X syndrome (known as FXS for short) is the most common known genetic cause of autism and the most common cause of inherited intellectual disability.
These results offer hope for patients with fragile X syndrome and their families, said Elizabeth Berry-Kravis, MD, PhD, a pediatric neurologist at Rush University Medical Center and principal investigator of the study. The majority of clinical outcome measures were in favor of the drug. These measures included performance-based assessments, biomarkers, and parent and physician-rated scales, which in combination, suggest a meaningful impact on the global FXS disease process. ....

Elizabeth Berry Kravis , David Hessl , Rush University Medical Center , National Institutes Of Health , Drug Administration , National Institutes , Toolbox Cognitive Battery , Tetra Therapeutics , எலிசபெத் பெர்ரி கிராவிஸ் , அவசரம் பல்கலைக்கழகம் மருத்துவ மையம் , தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் , தேசிய நிறுவனங்கள் , கருவிப்பெட்டி அறிவாற்றல் மின்கலம் , டெட்ரா சிகிச்சை ,